Cancer

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a…

11 months ago

Polarean and SimonMed Announce Collaboration to Advance Lung Imaging Innovation

One of the largest US outpatient medical imaging providers to introduce Xenon MRI platform to its network Polarean and SimonMed…

11 months ago

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Following a constructive Nasdaq hearing panel on January 7, 2025, Evaxion has been granted a 180-day extension in relation to…

11 months ago

March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma

Company prepares to advance to Phase 2 clinical trial in early 2025 HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March…

11 months ago

Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement

SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing…

11 months ago

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

NORWOOD, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced…

11 months ago

Anivive Secures $20 Million Investment from Leonid Capital Partners to Develop the Next Generation of Pet Health

Funding expands manufacturing readiness for Valley fever vaccineThis follows Anivive's $33MM NIAID contract for fungal vaccinesIn total, Anivive has secured…

11 months ago

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

- High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the…

11 months ago

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Study is the first randomized, controlled trial examining a vaccine’s effectiveness in controlling CMV in recipients of HSCT from vaccinated…

11 months ago

Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure

This expansion is in addition to the previously announced Microsoft for Startups program.PredicTcell, Tevogen Bio’s proprietary technology, is designed for…

11 months ago